scholarly journals LncRNA DLX6-AS1 as a potential molecular biomarker in the clinicopathology and prognosis of various cancers: a meta-analysis

2020 ◽  
Vol 40 (8) ◽  
Author(s):  
Shubo Tian ◽  
Jinglei Liu ◽  
Shuai Kong ◽  
Lipan Peng
Keyword(s):  
Survival Data ◽  
Poor Prognosis ◽  
Meta Analysis ◽  
Tumor Stage ◽  
Clinicopathological Characteristics ◽  
Clinicopathological Features ◽  
High Expression ◽  
Cochrane Library ◽  
Poor Overall Survival ◽  
The Cochrane Library

Abstract Objective: Recent studies have shown that distal-less homeobox 6 antisense 1 (DLX6-AS1) is aberrantly expressed in various cancers and is associated with poor prognosis. This meta-analysis is designed to investigate the effects of DLX6-AS1 expression on clinicopathological features and survival outcomes. Methods: All eligible studies were searched from Pubmed, Web of Science, Embase, the Cochrane Library, and Wanfang database, up to August 2019. The literature was selected according to the inclusion and exclusion criteria listed in this work, and the quality of each eligible study was assessed. Each patient’s clinicopathological features and survival data were analyzed using Stata12.0 software. Begg’s test and sensitivity analysis were also conducted. Results: A total of 12 articles were included, covering 841 patients. Results showed that high expression of DLX6-AS1 was significantly closely associated with poor overall survival in tumor patients (hazard ratio (HR) = 2.30, confidence interval (95% CI): 1.70–3.09, P<0.01). This meta-analysis also showed that overexpression of DLX6-AS1 was significantly associated with tumor stage (P<0.01), tumor size (P<0.01), lymph node metastasis (P<0.01), and distant metastasis (P<0.01). Begg’s test suggested no publication bias. Conclusion: This meta-analysis revealed that high expression of DLX6-AS1 was related to the advanced clinicopathological characteristics of human digestive system cancers (gastric cancer, esophageal cancer, colon cancer, pancreatic cancer, and hepatocellular carcinoma) and other cancers such as ovarian cancer, osteosarcoma and non-small cell lung cancer, and DLX6-AS1 has important predictive value for poor prognosis. However, more studies are needed to further corroborate these findings.

scholarly journals Prognostic Value of Circulating Tumour Cells detected with the CellSearch System in Esophageal Cancer Patients: A Systematic Review and Meta-Analysis

2020 ◽  
Author(s):  
Yiding Li ◽  
Guiling Wu ◽  
Wanli Yang ◽  
Xiaoqian Wang ◽  
Lili Duan ◽  
...  
Keyword(s):  
Therapeutic Response ◽  
Meta Analysis ◽  
Prognostic Significance ◽  
Pooled Analysis ◽  
Clinicopathological Characteristics ◽  
Cochrane Library ◽  
Cellsearch System ◽  
Poor Overall Survival ◽  
Response To Chemotherapy ◽  
The Cochrane Library

Abstract Background: Esophageal carcinoma (EC) is the seventh-most prevalent tumor in the world, which is still one of the primary causes of tumor-related death. Identifying noteworthy biomarkers for EC is particularly significant in guiding effective treatment. Recently, circulating tumor cells (CTCs) in peripheral blood (PB) were intensively discussed as prognostic markers in patients with EC. However, an ongoing controversy still exists regarding the prognostic significance of CTCs determined by the CellSearch system in EC sufferers. This meta-analysis was designed to approach this topic. Methods: We systematically conducted searches using PubMed, Medline, Web of Science and the Cochrane Library for relevant studies, which were published through February 20, 2020. Using the random-effects model, our study was performed in Review Manager software, with odds ratios (ORs), risk ratios (RRs), hazard ratios (HRs) and 95% confidence intervals (CIs) as the effect values. Results: Totally 7 articles were finally included in this study. For clinicopathological characteristics, the pooled results on TNM stage indicated that the III/IV group had higher rate of CTCs compared with the I/II group (OR=1.36, 95% CI: 0.68-2.71, I2=0%). Incidence of CTCs was higher in patients with T3/T4 stage (OR=2.92, 95% CI: 1.31-6.51, I2=0%) and distant metastasis group (OR=5.18, 95% CI: 2.38-11.25, I2=0%) compared to patients with T1/T2 stage or non-metastatic group. The pooled analysis revealed that CTC positivity detected in EC patients was correlated with poor overall survival (OS) (HR=2.83, 95% CI:1.99-4.03, I2=0%) and relapse-free survival (RFS) (HR=4.71, 95% CI:2.73-8.13, I2=0%). When pooling the estimated RR, a poor therapeutic response to chemoradiotherapy was discovered in patients with CTC positivity (RR=1.99, 95% CI:1.73-2.29, I2=60%). Conclusions: In summary, our meta-analysis demonstrated that CTCs positivity determined by the CellSearch system are correlated with the prognosis of EC patients and might indicate a poor therapeutic response to chemotherapy in EC patients.

The Presence of Intraductal Carcinoma of The Prostate Is Closely Correlated with Poor Prognosis: A Systematic Review and Meta-Analysis

2020 ◽  
Author(s):  
Yucong Zhang ◽  
Guoliang Sun ◽  
Delin Ma ◽  
Chao Wei ◽  
Haojie Shang ◽  
...  
Keyword(s):  
Survival Data ◽  
Poor Prognosis ◽  
Meta Analysis ◽  
Clinicopathological Characteristics ◽  
Intraductal Carcinoma ◽  
Treatment Modalities ◽  
Pathological Examination ◽  
Cochrane Library ◽  
Positive Surgical Margin ◽  
Carcinoma Of The Prostate

Abstract Background We aimed to confirm the predictive ability of the presence of intraductal carcinoma of the prostate (IDC-P) on prognosis and association between IDC-P and clinicopathological parameters.Methods Literatures were identified in PubMed, Cochrane Library, etc. up to December 1st, 2019. Hazard ratio (HR) for survival data and odds ratio (OR) for clinicopathological data with 95% confidence interval (CI) were extracted. Heterogeneity was evaluated by I 2 value and quality assessment by Newcastle-Ottawa Scale (NOS) criteria.Result A total of 4179 patients from 13 studies were included. The results showed IDC-P presence was significantly associated with poor progression-free survival (PFS) (HR = 2.31; 95% CI 1.96 to 2.73), cancer-specific survival (CSS) (HR=1.89; 95% CI 1.28 to 2.77) and overall survival (OS) (HR=2.14; 95% CI 1.53 to 3.01). In subgroup analysis, IDC-P presence was significantly associated with poor PFS in prostate cancer treated by radical prostatectomy (RP) (HR = 2.48; 95% CI 2.05 to 3.00) and those by radiotherapy (RT) (HR=2.83; 95% CI 1.65 to 4.85). For clinicopathological characteristics, IDC-P present patients showed significantly higher tumor clinical stage, Gleason score and probability of lymph node invasive, positive surgical margin and positive extraprostatic extension.Conclusion Our meta-analysis indicates presence of IDC-P is closely correlated with poor prognosis and adverse clinicopathological characteristics. Our data support the value and clinical utility of routine detection of IDC-P by pathological examination. These conclusions need further validation and prospective studies are needed to find better treatment modalities for patients with IDC-P other than traditional first-line androgen deprivation therapy.

scholarly journals Clinicopathological and Prognostic Significance of Long Non-coding RNA MIAT in Human Cancers: A Review and Meta-Analysis

2021 ◽  
Vol 12 ◽  
Author(s):  
Yongfeng Wang ◽  
Liangyin Fu ◽  
Tingting Lu ◽  
Guangming Zhang ◽  
Jiawei Zhang ◽  
...  
Keyword(s):  
Overall Survival ◽  
Tumor Marker ◽  
Meta Analysis ◽  
Clinicopathological Features ◽  
High Expression ◽  
Cochrane Library ◽  
Poor Overall Survival ◽  
Early Cancer Diagnosis ◽  
Patient Prognosis ◽  
The Relationship

Background: Although the treatment of cancer has made evident progress, its morbidity and mortality are still high. A tumor marker is a critical indicator for early cancer diagnosis, and timely cancer detection can efficiently help improve the prognosis of patients. Therefore, it is necessary to identify novel markers associated with cancer. LncRNA myocardial infarction associated transcript (MIAT) is a newly identified tumor marker, and in this study, we aimed to explore the relationship between MIAT and clinicopathological features and patient prognosis.Methods: We searched PubMed, Embase, Web of Science, and The Cochrane Library from inception to September 2020 to identify correlational studies. Then, we extracted valid data and used Stata software to make forest plots. We used the hazard ratio (HR) or odds ratio (OR) with 95% CI to evaluate the relationship between aberrant expression of MIAT and patients' prognosis and clinicopathological features.Results: The study included 21 studies, containing 2,048 patients. Meta-analysis showed that overexpression of lncRNA MIAT was associated with poor overall survival (OS) (HR = 1.60, 95% CI, 1.31–1.96, p < 0.001). In addition, high expression of MIAT could forecast tumor size (OR = 2.26, 95% CI 1.34–3.81, p = 0.002), distant metastasis (OR = 2.54, 95% CI 1.84–3.50, p < 0.001), TNM stage (OR = 2.38, 95% CI 1.36–4.18, p = 0.002), lymph node metastasis (OR = 2.59, 95% CI 1.25–5.36, p = 0.011), and the degree of differentiation (OR = 2.65, 95% CI 1.54–4.58, p < 0.001). However, other clinicopathological features, including age (OR = 1.07, 95% CI 0.87–1.32, p = 0.516), gender (OR = 0.95, 95% CI 0.77–1.19, p = 0.668), and histology (OR = 0.72, 95% CI 0.48–1.10, p = 0.128) were not significantly different from high expression of MIAT.Conclusions: Our study showed that overexpression of MIAT is related to poor overall survival and clinicopathological features. MIAT can be considered a novel tumor marker to help diagnose tumors earlier and improve patient prognosis.

scholarly journals BRAFV600E mutation in papillary thyroid microcarcinoma: a meta-analysis

2015 ◽  
Vol 22 (2) ◽  
pp. 159-168 ◽  
Author(s):  
Fei Li ◽  
Guangqi Chen ◽  
Chunjun Sheng ◽  
Aaron M Gusdon ◽  
Yueye Huang ◽  
...  
Keyword(s):  
Meta Analysis ◽  
Clinicopathological Characteristics ◽  
Clinicopathological Features ◽  
Papillary Thyroid Microcarcinoma ◽  
Cochrane Library ◽  
Papillary Thyroid ◽  
Brafv600e Mutation ◽  
Thyroid Microcarcinoma ◽  
Significant Difference ◽  
The Cochrane Library

The prognostic value of the BRAFV600E mutation, resulting in poor clinical outcomes of papillary thyroid carcinoma, has been generally confirmed. However, the association of BRAFV600E with aggressive clinical behaviors of papillary thyroid microcarcinoma (PTMC) has not been firmly established in individual studies. We performed this meta-analysis to examine the relationship between BRAFV600E mutation and the clinicopathological features of PTMC. We conducted a systematic search in PubMed, EMBASE, and the Cochrane library for relevant studies. We selected all the studies that reported clinicopathological features of PTMC patients with information available on BRAFV600E mutation status. Nineteen studies involving a total of 3437 patients met these selection criteria and were included in the analyses. The average prevalence of the BRAFV600E mutation was 47.48%, with no significant difference with respect to patient sex (male versus female) and age (younger than 45 years versus 45 years or older). Compared with the WT BRAF gene, the BRAFV600E mutation was associated with tumor multifocality (odds ratio (OR) 1.38; 95% CI, 1.04–1.82), extrathyroidal extension (OR 3.09; 95% CI, 2.24–4.26), lymph node metastases (OR 2.43; 95% CI, 1.28–4.60), and advanced stage (OR 2.39; 95% CI, 1.38–4.15) of PTMC. Thus, our findings from this large meta-analysis definitively demonstrate that BRAFV600E-mutation-positive PTMC are more likely to manifest with aggressive clinicopathological characteristics. In appropriate clinical settings, testing for the BRAFV600E mutation is likely to be useful in assisting the risk stratification and management of PTMC.

scholarly journals The value of lncRNAs as prognostic biomarkers on clinical outcomes in osteosarcoma: a meta-analysis

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Wenchao Zhang ◽  
Xiaolei Ren ◽  
Lin Qi ◽  
Chenghao Zhang ◽  
Chao Tu ◽  
...  
Keyword(s):  
Web Of Science ◽  
Meta Analysis ◽  
Positive Outcome ◽  
Clinical Applications ◽  
Clinicopathological Features ◽  
Cochrane Library ◽  
Human Osteosarcoma ◽  
Non Coding Rna ◽  
The Cochrane Library ◽  
Long Non Coding Rna

Abstract Background In recent years, emerging studies have demonstrated critical functions and potential clinical applications of long non-coding RNA (lncRNA) in osteosarcoma. To further validate the prognostic value of multiple lncRNAs, we have conducted this updated meta-analysis. Methods Literature retrieval was conducted by searching PubMed, Web of Science and the Cochrane Library (last update by October 2, 2019). A meta-analysis was performed to explore association between lncRNAs expression and overall survival (OS) of osteosarcoma patients. Relationships between lncRNAs expression and other clinicopathological features were also analyzed respectively. Results Overall, 4351 patients from 62 studies were included in this meta-analysis and 25 lncRNAs were identified. Pooled analyses showed that high expression of 14 lncRNAs connoted worse OS, while two lncRNAs were associated with positive outcome. Further, analysis toward osteosarcoma clinicopathologic features demonstrated that overexpression of TUG1 and XIST indicated poor clinical parameters of patients. Conclusions This meta-analysis has elucidated the prognostic potential of 16 lncRNAs in human osteosarcoma. Evidently, desperate expression and functional targets of these lncRNAs offer new approaches for prognosis and therapy of osteosarcoma.

scholarly journals Prognostic Value of Circular RNA ciRS-7 in Various Cancers: A PRISMA-Compliant Meta-Analysis

2020 ◽  
Vol 2020 ◽  
pp. 1-9 ◽  
Author(s):  
Guangwei Tian ◽  
Guang Li ◽  
Lin Guan ◽  
Zihui Wang ◽  
Nan Li
Keyword(s):  
Meta Analysis ◽  
Prognostic Indicator ◽  
Tumor Stage ◽  
Circular Rna ◽  
Cochrane Library ◽  
Size Analysis ◽  
Circular Rnas ◽  
Hazard Ratios ◽  
Potential Biomarker ◽  
The Cochrane Library

Background. Circular RNAs (circRNAs) have been shown to be involved in tumorigenesis. As a member of circRNAs, ciRS-7 is thought to be a negative prognostic indicator in multiple types of cancer. The present study aimed to comprehensively explore the value of ciRS-7 in tumor malignancy. Materials and Methods. A systematic review of PubMed, Web of Science, and the Cochrane library was carried out to examine the related studies. The pooled odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (95% CIs) were calculated from the available publications by STATA 12.0. Subgroup analysis, publication bias, sensitivity analysis, and meta-regression were conducted. Results. This meta-analysis included 1,714 patients from 13 cohorts. The results suggested that high ciRS-7 expression was significantly associated with overall survival (OS) (HR = 2.17, 95% CI = 1.50–3.15, P<0.001) in various cancers. Stratified analyses indicated that elevated levels of ciRS-7 appeared to be a powerful prognostic biomarker for patients with non-small-cell lung cancer (NSCLC) (HR: 2.50, 95% CI: 1.07–6.07, P=0.035), colorectal cancer (CRC) (HR: 1.95, 95% CI: 1.34–2.84, P<0.001), and gastric cancer (GC) (HR: 2.32, 95% CI: 1.48–3.64, P<0.001). A similar effect was also observed in subgroup of sample size, analysis method, and cutoff value, except for ethnicity. The increased ciRS-7 expression was associated with a higher tumor stage (OR = 2.30, 95% CI: 1.69–3.13, P<0.001). Conclusions. High expression of ciRS-7 has a significant correlation with the high stage in various cancers, and ciRS-7 is intimately associated with an adverse OS in numerous cancers. Thus, ciRS-7 may act as a potential biomarker for the development of malignancies.

scholarly journals Prognostic and clinicopathological significance of circular RNA circ-ITCH expression in cancer patients: a meta-analysis

2020 ◽  
Author(s):  
Xiao-Dong Sun ◽  
Chen Huan ◽  
Da-Wei Sun ◽  
Guo-yue Lv
Keyword(s):  
Cancer Patients ◽  
Meta Analysis ◽  
Univariate Analysis ◽  
Circular Rna ◽  
Clinicopathological Features ◽  
Molecular Therapy ◽  
Cochrane Library ◽  
Circular Rnas ◽  
Poor Overall Survival ◽  
Therapy Target

Abstract Background: Circular RNAs are a class of noncoding RNAs, and several members of them have been reported to be capable of regulating various biological processes and predicting the outcome of disease. Among them, circular RNA circ-ITCH has been identified to be aberrantly expressed and associated with disease progression in diverse cancers. However, the relationship between circ-ITCH expression and clinicopathological features, as well as prognosis of cancers, remains inconclusive. Material and methods: Up to April 30th, 2020, relevant articles were searched in PubMed, Web of Science, Cochrane library, Embase, CNKI and Wanfang databases. A meta-analysis was performed to investigate the clinical significance of circ-ITCH in cancers by systematically summarizing all eligible literatures. Results: A total of 1 456 patients from 12 studies were included in this meta-analysis. The results showed that cancer patients with low circ-ITCH expression were more susceptible to develop lymph node metastasis (OR=2.26, 95% CI:1.63-3.13, P=0.000), and were associated with larger tumor size (OR=2.69, 95%CI:1.76-4.12, P=0.000), advanced TNM stage (OR=2.57, 95%CI:1.63-4.06, P=0.000), as well as poor overall survival (OS) (HR=2.51, 95%CI:2.09-3.02, P=0.000, univariate analysis; HR=2.69, 95%CI:1.82-3.96, P=0.000, multivariate analysis). Conclusion: Low circ-ITCH expression was significantly associated with aggressive clinicopathological features and unfavorable outcome in various cancers. Therefore, circ-ITCH may serve as a molecular therapy target and a prognostic marker in cancers.

scholarly journals Prognostic and Clinicopathological Significance of Circular RNA circ-ITCH Expression in Cancer Patients: A Meta-analysis

2021 ◽  
Vol 2021 ◽  
pp. 1-13
Author(s):  
Xiao-Dong Sun ◽  
Chen Huan ◽  
Da-Wei Sun ◽  
Guo-Yue Lv
Keyword(s):  
Cancer Patients ◽  
Meta Analysis ◽  
Univariate Analysis ◽  
Circular Rna ◽  
Clinicopathological Features ◽  
Molecular Therapy ◽  
Cochrane Library ◽  
Circular Rnas ◽  
Poor Overall Survival ◽  
Therapy Target

Circular RNAs are a class of RNAs with a covalently closed configuration, and several members of them have been reported to be capable of regulating various biological processes and predicting the outcome of disease. Among them, circular RNA circ-ITCH has been identified to be aberrantly expressed and associated with disease progression in diverse cancers. However, the correlation of circ-ITCH expression with clinicopathological features, as well as the prognosis of cancers, remains inconclusive. Therefore, a meta-analysis was performed to investigate the clinical significance of circ-ITCH in cancers by systematically summarizing all eligible literatures. Up to August 31, 2020, relevant articles were searched in PubMed, Web of Science, Cochrane library, Embase, CNKI, and Wanfang databases. Pooled hazard ratios (HRs) and odds ratios (ORs) with corresponding 95% confidence intervals (CIs) were calculated. A total of 1604 patients from 14 studies were included in this meta-analysis. The results showed that cancer patients with low circ-ITCH expression were more susceptible to develop lymph node metastasis ( OR = 2.25 , 95% CI: 1.67-3.02, p ≤ 0.01 ), larger tumor size ( OR = 3.01 , 95% CI: 2.01-4.52, p ≤ 0.01 ), advanced TNM stage ( OR = 2.82 , 95% CI: 1.92-4.14, p ≤ 0.01 ), and poor overall survival (OS) ( HR = 2.45 , 95% CI: 2.07–2.90, p ≤ 0.01 , univariate analysis; HR = 2.69 , 95% CI: 1.82-3.96, p ≤ 0.01 , multivariate analysis). Thus, low circ-ITCH expression was significantly associated with aggressive clinicopathological features and unfavorable outcome in various cancers. Therefore, circ-ITCH may serve as a molecular therapy target and a prognostic marker in human cancers.

scholarly journals Role of TSP-1 as prognostic marker in various cancers: a systematic review and meta-analysis

2020 ◽  
Author(s):  
Shengjie Sun ◽  
Huiyu Dong ◽  
Tao Yan ◽  
Junchen Li ◽  
Chao Liang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Poor Prognosis ◽  
Meta Analysis ◽  
Gynecological Cancer ◽  
Disease Free Survival ◽  
Progression Free Survival ◽  
Cochrane Library ◽  
Poor Overall Survival ◽  
Free Survival ◽  
The Impact

Abstract Background Published studies present conflicting data regarding the impact of Thrombospondin-1 (TSP-1) expression on prognosis of various cancers . We performed this meta-analysis to clarify the preliminary predictive value of TSP-1. Methods Twenty-four studies with a total of 2379 patients were included. A comprehensive literature search was performed by using PubMed, Cochrane Library, Web of Science, Embase, and hand searches were also conducted of relevant bibliographies. Pooled hazard ratio s ( HRs ) with 95% confidence intervals ( CIs ) for patient survival and disease recurrence were initially identified to explore relationships between TSP-1 expression and patient prognosis. Results A total of 24 eligible studies were included in this meta-analysis. Our results showed that high level of TSP-1 was correlated significantly with poor overall survival ( OS ) (HR=1.40, 95% CI: 1.17~1.68). However, high TSP-1 expression predicted no significant impact on progression-free survival ( PFS )/ metastasis-free survival (MFS ) (HR=1.35, 95%CI: 0.87-2.10) and disease-free survival ( DFS )/ recurrence-free survival ( RFS ) (HR = 1.40, 95%CI: 0.77–2.53). In addition, we performed subgroup analyses which showed that high TSP-1 expression predicted poor prognosis in breast cancer and gynecological cancer. Conclusions Our findings indicated high TSP-1 expression may serve as a promising biomarker of poor prognosis and novel therapeutic target in cancers, especially in breast cancer and gynecological cancer.

scholarly journals High BANCR expression is associated with worse prognosis in human malignant carcinomas: an updated systematic review and meta-analysis

BMC Cancer ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Shixu Fang ◽  
Zhou Liu ◽  
Qiang Guo ◽  
Cheng Chen ◽  
Xixian Ke ◽  
...  
Keyword(s):  
Noncoding Rna ◽  
Smoking Status ◽  
Meta Analysis ◽  
Strong Relationship ◽  
Tumor Stage ◽  
Cochrane Library ◽  
Advanced Tumor Stage ◽  
China National Knowledge Infrastructure ◽  
Poor Overall Survival ◽  
Advanced Tumor

Abstract Background BRAF-activated noncoding RNA (BANCR) is aberrantly expressed in various tumor tissues and has been confirmed to function as a tumor suppressor or oncogene in many types of cancers. Considering the conflicting results and insufficient sampling, a meta-analysis was performed to explore the prognostic value of BANCR in various carcinomas. Methods A comprehensive literature search of PubMed, Web of Science, EMBASE, Cochrane Library and the China National Knowledge Infrastructure (CNKI) was conducted to collect relevant articles. Results The pooled results showed a strong relationship between high BANCR expression and poor overall survival (OS) (HR (hazard ratio) =1.60, 95% confidence interval (CI): 1.19–2.15, P = 0.002) and recurrence-free survival (RFS) (HR = 1.53, 95% CI: 1.27–1.85, P < 0.00001). In addition, high BANCR expression predicted advanced tumor stage (OR (odds ratio) =2.39, 95% CI: 1.26–4.53, P = 0.008), presence of lymph node metastasis (OR = 2.03, 95% CI: 1.08–3.83, P = 0.03), positive distant metastasis (OR = 3.08, 95% CI: 1.92–4.96, P < 0.00001) and larger tumor sizes (OR = 1.63, 95% CI: 1.09–2.46, P = 0.02). However, no associations were found for smoking status (OR = 1.01, 95% CI: 0.65–1.56, P = 0.98), age (OR = 0.88, 95% CI: 0.71–1.09, P = 0.236) and sex (OR = 0.91, 95% CI: 0.72–1.16, P = 0.469). The sensitivity analysis of OS showed that the results of each publication were almost consistent with the combined results, and the merged results have high robustness and reliability. Conclusions The results showed that elevated BANCR expression was associated with unfavorable prognosis for most cancer patients, and BANCR could serve as a promising therapeutic target and independent prognostic predictor in most of cancer types.

Sign in / Sign up

Export Citation Format

Share Document